JP7168938B2 - パラミクソウイルスおよび/またはニューモウイルスのfタンパク質を表示する自己アセンブリするタンパク質ナノ構造およびその使用 - Google Patents

パラミクソウイルスおよび/またはニューモウイルスのfタンパク質を表示する自己アセンブリするタンパク質ナノ構造およびその使用 Download PDF

Info

Publication number
JP7168938B2
JP7168938B2 JP2019554692A JP2019554692A JP7168938B2 JP 7168938 B2 JP7168938 B2 JP 7168938B2 JP 2019554692 A JP2019554692 A JP 2019554692A JP 2019554692 A JP2019554692 A JP 2019554692A JP 7168938 B2 JP7168938 B2 JP 7168938B2
Authority
JP
Japan
Prior art keywords
seq
polypeptide
nanostructure
cav1
nanostructures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019554692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515280A5 (cg-RX-API-DMAC7.html
JP2020515280A (ja
Inventor
キング,ネイル,ピー.
ベイカー,デイビッド
ニッカーソン,ブルーク
スチュワート,ランス,ジョセフ
ペレス,ローラン
ランザベッキア,アントニオ
マーカンダリ,ジェシカ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of JP2020515280A publication Critical patent/JP2020515280A/ja
Publication of JP2020515280A5 publication Critical patent/JP2020515280A5/ja
Priority to JP2022167524A priority Critical patent/JP7541701B2/ja
Application granted granted Critical
Publication of JP7168938B2 publication Critical patent/JP7168938B2/ja
Priority to JP2024132065A priority patent/JP2024160321A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019554692A 2017-04-04 2018-04-03 パラミクソウイルスおよび/またはニューモウイルスのfタンパク質を表示する自己アセンブリするタンパク質ナノ構造およびその使用 Active JP7168938B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022167524A JP7541701B2 (ja) 2017-04-04 2022-10-19 パラミクソウイルスおよび/またはニューモウイルスのfタンパク質を表示する自己アセンブリするタンパク質ナノ構造およびその使用
JP2024132065A JP2024160321A (ja) 2017-04-04 2024-08-08 パラミクソウイルスおよび/またはニューモウイルスのfタンパク質を表示する自己アセンブリするタンパク質ナノ構造およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762481331P 2017-04-04 2017-04-04
US62/481,331 2017-04-04
PCT/US2018/025880 WO2018187325A1 (en) 2017-04-04 2018-04-03 Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022167524A Division JP7541701B2 (ja) 2017-04-04 2022-10-19 パラミクソウイルスおよび/またはニューモウイルスのfタンパク質を表示する自己アセンブリするタンパク質ナノ構造およびその使用

Publications (3)

Publication Number Publication Date
JP2020515280A JP2020515280A (ja) 2020-05-28
JP2020515280A5 JP2020515280A5 (cg-RX-API-DMAC7.html) 2021-05-06
JP7168938B2 true JP7168938B2 (ja) 2022-11-10

Family

ID=62116943

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019554692A Active JP7168938B2 (ja) 2017-04-04 2018-04-03 パラミクソウイルスおよび/またはニューモウイルスのfタンパク質を表示する自己アセンブリするタンパク質ナノ構造およびその使用
JP2022167524A Active JP7541701B2 (ja) 2017-04-04 2022-10-19 パラミクソウイルスおよび/またはニューモウイルスのfタンパク質を表示する自己アセンブリするタンパク質ナノ構造およびその使用
JP2024132065A Pending JP2024160321A (ja) 2017-04-04 2024-08-08 パラミクソウイルスおよび/またはニューモウイルスのfタンパク質を表示する自己アセンブリするタンパク質ナノ構造およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022167524A Active JP7541701B2 (ja) 2017-04-04 2022-10-19 パラミクソウイルスおよび/またはニューモウイルスのfタンパク質を表示する自己アセンブリするタンパク質ナノ構造およびその使用
JP2024132065A Pending JP2024160321A (ja) 2017-04-04 2024-08-08 パラミクソウイルスおよび/またはニューモウイルスのfタンパク質を表示する自己アセンブリするタンパク質ナノ構造およびその使用

Country Status (24)

Country Link
US (4) US11192926B2 (cg-RX-API-DMAC7.html)
EP (2) EP3606942B1 (cg-RX-API-DMAC7.html)
JP (3) JP7168938B2 (cg-RX-API-DMAC7.html)
KR (2) KR102774312B1 (cg-RX-API-DMAC7.html)
CN (3) CN115779077A (cg-RX-API-DMAC7.html)
AU (3) AU2018249533C1 (cg-RX-API-DMAC7.html)
BR (1) BR112019020661A2 (cg-RX-API-DMAC7.html)
CA (1) CA3058794A1 (cg-RX-API-DMAC7.html)
DK (1) DK3606942T3 (cg-RX-API-DMAC7.html)
ES (1) ES3040563T3 (cg-RX-API-DMAC7.html)
FI (1) FI3606942T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251060T1 (cg-RX-API-DMAC7.html)
HU (1) HUE073526T2 (cg-RX-API-DMAC7.html)
IL (2) IL322023A (cg-RX-API-DMAC7.html)
LT (1) LT3606942T (cg-RX-API-DMAC7.html)
MX (2) MX2019011869A (cg-RX-API-DMAC7.html)
PH (1) PH12019502276A1 (cg-RX-API-DMAC7.html)
PL (1) PL3606942T3 (cg-RX-API-DMAC7.html)
PT (1) PT3606942T (cg-RX-API-DMAC7.html)
RS (1) RS67190B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201908999QA (cg-RX-API-DMAC7.html)
SI (1) SI3606942T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500317T1 (cg-RX-API-DMAC7.html)
WO (1) WO2018187325A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023002680A (ja) * 2017-04-04 2023-01-10 ユニヴァーシティ オブ ワシントン パラミクソウイルスおよび/またはニューモウイルスのfタンパク質を表示する自己アセンブリするタンパク質ナノ構造およびその使用

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9630994B2 (en) * 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
CN112088014B (zh) * 2018-02-28 2026-03-24 华盛顿大学 自组装纳米结构疫苗
CN113423718A (zh) 2019-02-08 2021-09-21 美国政府(由卫生和人类服务部的部长所代表) 基于纳米颗粒的流感病毒疫苗及其用途
JP7818504B2 (ja) * 2019-09-04 2026-02-20 ユニヴァーシティ オブ ワシントン パラミクソウイルスおよび/またはニューモウイルスのfタンパク質を提示する自己組織化タンパク質ナノ構造体ならびにその使用
CN110878128A (zh) * 2019-11-04 2020-03-13 中国疾病预防控制中心病毒病预防控制所 一种人呼吸道合胞病毒粘膜疫苗及其制备方法和应用
KR20220133911A (ko) * 2020-01-30 2022-10-05 모더나티엑스, 인크. 호흡기 바이러스 면역화 조성물
EP4103230A1 (en) * 2020-02-14 2022-12-21 University of Washington Polypeptides, compositions, and their use to treat or limit development of an infection
KR20220142471A (ko) * 2020-02-14 2022-10-21 유니버시티 오브 워싱턴 폴리펩타이드 및 그 용도
US20230227790A1 (en) * 2020-06-09 2023-07-20 Scot R. Shepard Method of assemblying two-component virus-like particle
US20240050559A1 (en) * 2020-06-09 2024-02-15 Icosavax, Inc. Method of making virus-like particle
IL320367A (en) 2020-10-09 2025-06-01 Univ Texas Prefusion-stabilized hmpv f proteins
CN111991556B (zh) * 2020-10-29 2021-03-02 中山大学 SARS-CoV-2 RBD共轭纳米颗粒疫苗
KR20230107621A (ko) * 2020-11-13 2023-07-17 아이코사백스, 인크. 메타뉴모바이러스에 대한 단백질-기반 나노입자 백신
CN112778404B (zh) * 2021-01-28 2022-11-29 中山大学 一种含EB病毒gHgL蛋白的自组装纳米颗粒及其制备方法与应用
JP2024520730A (ja) * 2021-06-07 2024-05-24 アイコサバックス, インコーポレイテッド コロナウイルスに対するウイルス様粒子ワクチン
IL310628A (en) * 2021-08-10 2024-04-01 Icosavax Inc Virus-like particle vaccine for respiratory syncytial virus
JP2025517362A (ja) 2022-05-17 2025-06-05 アイコサバックス, インコーポレイテッド パラミクソウイルス用の多価ワクチン及びその使用
EP4626470A2 (en) * 2022-11-29 2025-10-08 The Scripps Research Institute Vaccines containing novel nanoparticle scaffolds
WO2024131862A1 (zh) * 2022-12-22 2024-06-27 北京吉诺卫生物科技有限公司 一种rsv疫苗及其制备方法与应用
CN118108812B (zh) * 2023-05-04 2025-04-15 国药中生生物技术研究院有限公司 Rsv f蛋白的突变体
TW202519273A (zh) * 2023-07-18 2025-05-16 瑞典商阿斯特捷利康公司 Rsv疫苗
CN119930762A (zh) * 2023-11-03 2025-05-06 广东蓝玉生物科技有限公司 非洲猪瘟病毒ep153r蛋白的免疫原性组合物及其应用
CN121758570A (zh) * 2023-11-03 2026-03-31 广东蓝玉生物科技有限公司 非洲猪瘟病毒CD2v蛋白的免疫原性组合物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014124301A1 (en) 2013-02-07 2014-08-14 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
WO2015177312A1 (en) 2014-05-22 2015-11-26 Glaxosmithkline Biologicals Sa Rsvf trimerization domains
US20160122392A1 (en) 2014-11-03 2016-05-05 University Of Washington Polypeptides for use in self-assembling protein nanostructures
JP2016533332A (ja) 2013-09-24 2016-10-27 マサチューセッツ インスティテュート オブ テクノロジー 自己集合型ナノ粒子ワクチン

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4238904A1 (de) 1992-11-19 1994-05-26 Basf Ag Riboflavin-Synthese in Hefen
DE69924712T2 (de) 1998-03-04 2006-03-09 Exxonmobil Chemical Patents Inc., Baytown Nicht koordinierende anionen für die polymerisation von olefinen
US6303767B1 (en) 1998-11-05 2001-10-16 Kosan Biosciences, Inc. Nucleic acids encoding narbonolide polyketide synthase enzymes from streptomyces narbonensis
JP2000152791A (ja) 1998-11-11 2000-06-06 E I Du Pont De Nemours & Co ルマジンシンターゼおよびリボフラビンシンターゼ
US20040005672A1 (en) 2002-02-22 2004-01-08 Santi Daniel V. Heterologous production of polyketides
WO2004024744A2 (en) 2002-07-31 2004-03-25 The Board Of Trustees Of The Leland Stanford Junior University Production of glycosylated macrolides in e. coli
US7964196B2 (en) 2004-05-25 2011-06-21 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
JP2008513540A (ja) 2004-09-21 2008-05-01 メディミューン,インコーポレーテッド 呼吸器合胞体ウイルスに対する抗体及び該ウイルス用のワクチンを製造する方法
US8563002B2 (en) 2007-12-24 2013-10-22 Glaxosmithkline Biologicals, S.A. Recombinant RSV antigens
US9102526B2 (en) 2008-08-12 2015-08-11 Imiplex Llc Node polypeptides for nanostructure assembly
WO2010019725A2 (en) 2008-08-12 2010-02-18 Salemme Francis R Node polypeptides for nanostructure assembly
GB0817507D0 (en) 2008-09-24 2008-10-29 Ucl Business Plc Protein cages
ES2987238T3 (es) 2008-12-09 2024-11-14 Novavax Inc Proteínas F del RSV modificadas y métodos de su uso
US20110200560A1 (en) 2009-05-26 2011-08-18 Massachusetts Institute Of Technology Non-ionic self-assembling peptides and uses thereof
WO2011017835A1 (en) 2009-08-11 2011-02-17 Nanjing University Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
US8920812B2 (en) 2009-11-03 2014-12-30 Takeda Vaccines, Inc. Chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus Gag-based VLPS
CN106008716B (zh) 2010-07-07 2019-08-13 人工细胞科技公司 呼吸道合胞病毒抗原组合物和方法
WO2012048115A2 (en) * 2010-10-06 2012-04-12 University Of Washington Through Its Center For Commercialization Polypeptides and their use in treating and limiting respiratory syncytial virus infection
RS56748B1 (sr) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fuzioni rsv f antigeni
WO2013044203A2 (en) 2011-09-23 2013-03-28 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES Novel influenza hemagglutinin protein-based vaccines
SG10201602434UA (en) 2011-09-30 2016-05-30 Novavax Inc Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
EP2766030A4 (en) 2011-10-12 2015-09-16 Univ Washington MANIPULATED OUTER DOMAIN OF HV-GP120 AND MUTANTS THEREOF
WO2013155205A1 (en) 2012-04-10 2013-10-17 The Trustees Of The University Of Pennsylvania Human respiratory syncytial virus concensus antigens, nucleic acid constructs and vaccines made thereform, and methods of using same
US8969521B2 (en) 2012-04-11 2015-03-03 University Of Washington Through Its Center For Commercialization General method for designing self-assembling protein nanomaterials
WO2014005643A1 (en) 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
AU2013286093B2 (en) 2012-07-06 2018-01-04 Novartis Ag Complexes of cytomegalovirus proteins
SI2879702T1 (sl) 2012-08-01 2020-02-28 Bavarian Nordic A/S Cepivo na osnovi rekombinantnega modificiranega virusa vakcinacije Ankara (MVA) proti respiratornemu sincitialnemu virusu (RSV)
KR20150085843A (ko) 2012-11-20 2015-07-24 글락소스미스클라인 바이오로지칼즈 에스.에이. Rsv f 융합전 삼합체
US20140141037A1 (en) 2012-11-20 2014-05-22 Novartis Ag Rsv f prefusion trimers
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
EP4421177A3 (en) 2013-03-13 2024-12-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
US9060975B2 (en) 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
US9856313B2 (en) 2013-03-15 2018-01-02 Xiamen University Epitope of RSV fusion protein and antibody recognizing the same
PT2988780T (pt) 2013-04-25 2019-03-25 Janssen Vaccines & Prevention Bv Polipeptídeos f de pré-fusão do rsv solúveis estabilizados
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
CN104436202B (zh) 2013-09-12 2017-07-28 中国科学院深圳先进技术研究院 聚合物纳米颗粒、其制备方法及疫苗组合物、疫苗制剂及其制备方法
US20150166610A1 (en) 2013-10-14 2015-06-18 Glaxosmithkline Biologicals, S.A. Recombinant rsv antigens
AU2015205567B2 (en) 2014-01-09 2019-04-04 Alpha-O Peptides Ag Flagellin-containing protein nanoparticles as a vaccine platform
KR102463632B1 (ko) 2014-07-10 2022-11-03 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 백신 및 이의 용도
BR112017014219A2 (en) 2014-12-31 2018-03-06 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services multivalent nanoparticle-based vaccines
WO2016138525A1 (en) 2015-02-27 2016-09-01 University Of Washington Polypeptide assemblies and methods for the production thereof
WO2016160166A1 (en) 2015-03-30 2016-10-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic rsv polypeptides
AU2016289496B2 (en) 2015-07-07 2021-02-04 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
CN107847580B (zh) 2015-07-07 2022-08-12 扬森疫苗与预防公司 针对rsv的疫苗
US10024198B2 (en) 2015-08-13 2018-07-17 Echogen Power Systems, Llc Heat engine system including an integrated cooling circuit
CN108348593B (zh) * 2015-08-31 2022-08-16 泰克诺瓦克斯股份有限公司 基于人呼吸道合胞病毒(hrsv)病毒样颗粒(vlps)的疫苗
CN114617959A (zh) 2015-09-03 2022-06-14 诺瓦瓦克斯股份有限公司 具有改进的稳定性和免疫原性的疫苗组合物
WO2017066484A2 (en) 2015-10-13 2017-04-20 Carter Daniel C Nsp10 self-assembling fusion proteins for vaccines, therapeutics, diagnostics and other nanomaterial applications
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
SG11201803581VA (en) 2015-10-29 2018-05-30 Univ Emory Chimeric RSV, Immunogenic Compositions, and Methods of Use
RU2723039C2 (ru) 2015-12-23 2020-06-08 Пфайзер Инк. Мутанты белка f rsv
CN115960263A (zh) 2016-03-29 2023-04-14 美国政府(由卫生和人类服务部的部长所代表) 取代修饰的融合前rsv f蛋白及其用途
MX2018012094A (es) 2016-04-05 2019-01-10 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas.
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
SG11201810078PA (en) 2016-05-30 2018-12-28 Janssen Vaccines & Prevention Bv Stabilized pre-fusion rsv f proteins
EP3474893A1 (en) 2016-06-27 2019-05-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
WO2018109220A2 (en) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
EP3606942B1 (en) 2017-04-04 2025-06-11 University of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
CN107157933B (zh) 2017-05-04 2021-05-11 同济大学 一种蛋白自组装新型纳米疫苗及其制备方法
CN112088014B (zh) 2018-02-28 2026-03-24 华盛顿大学 自组装纳米结构疫苗

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014124301A1 (en) 2013-02-07 2014-08-14 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
JP2016533332A (ja) 2013-09-24 2016-10-27 マサチューセッツ インスティテュート オブ テクノロジー 自己集合型ナノ粒子ワクチン
WO2015177312A1 (en) 2014-05-22 2015-11-26 Glaxosmithkline Biologicals Sa Rsvf trimerization domains
US20160122392A1 (en) 2014-11-03 2016-05-05 University Of Washington Polypeptides for use in self-assembling protein nanostructures

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Science,2013年,vol.342, issue 6158,p.592-598

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023002680A (ja) * 2017-04-04 2023-01-10 ユニヴァーシティ オブ ワシントン パラミクソウイルスおよび/またはニューモウイルスのfタンパク質を表示する自己アセンブリするタンパク質ナノ構造およびその使用
JP7541701B2 (ja) 2017-04-04 2024-08-29 ユニヴァーシティ オブ ワシントン パラミクソウイルスおよび/またはニューモウイルスのfタンパク質を表示する自己アセンブリするタンパク質ナノ構造およびその使用

Also Published As

Publication number Publication date
SG11201908999QA (en) 2019-10-30
KR20240161683A (ko) 2024-11-12
RS67190B1 (sr) 2025-10-31
CN115779077A (zh) 2023-03-14
MX2019011869A (es) 2020-01-09
SMT202500317T1 (it) 2025-11-10
FI3606942T3 (fi) 2025-08-29
US20250263445A1 (en) 2025-08-21
CA3058794A1 (en) 2018-10-11
PT3606942T (pt) 2025-09-01
BR112019020661A2 (pt) 2020-05-05
US11732011B2 (en) 2023-08-22
RU2019130167A3 (cg-RX-API-DMAC7.html) 2021-12-22
PH12019502276A1 (en) 2020-09-28
KR20190140916A (ko) 2019-12-20
KR102774312B1 (ko) 2025-03-05
JP2024160321A (ja) 2024-11-13
AU2018249533A1 (en) 2019-10-17
IL322023A (en) 2025-09-01
EP3606942A1 (en) 2020-02-12
US12275757B2 (en) 2025-04-15
PL3606942T3 (pl) 2025-11-12
WO2018187325A1 (en) 2018-10-11
HUE073526T2 (hu) 2026-01-28
IL269643B1 (en) 2026-07-01
AU2022202787A1 (en) 2022-05-19
SI3606942T1 (sl) 2025-11-28
US11192926B2 (en) 2021-12-07
MX2023004704A (es) 2023-05-09
AU2024220089A1 (en) 2024-10-17
US20240150411A1 (en) 2024-05-09
RU2019130167A (ru) 2021-05-05
DK3606942T3 (da) 2025-09-08
LT3606942T (lt) 2025-10-10
AU2018249533B2 (en) 2022-01-27
IL269643A (en) 2019-11-28
AU2022202787B2 (en) 2024-07-04
AU2018249533C1 (en) 2023-10-12
AU2022202787C1 (en) 2025-01-30
EP3606942B1 (en) 2025-06-11
EP4559869A3 (en) 2025-08-20
ES3040563T3 (en) 2025-11-03
HRP20251060T1 (hr) 2025-11-07
JP2023002680A (ja) 2023-01-10
US20200392187A1 (en) 2020-12-17
CN110603262A (zh) 2019-12-20
JP2020515280A (ja) 2020-05-28
CN115947873A (zh) 2023-04-11
US20220169681A1 (en) 2022-06-02
JP7541701B2 (ja) 2024-08-29
EP4559869A2 (en) 2025-05-28

Similar Documents

Publication Publication Date Title
JP7541701B2 (ja) パラミクソウイルスおよび/またはニューモウイルスのfタンパク質を表示する自己アセンブリするタンパク質ナノ構造およびその使用
CN112088014B (zh) 自组装纳米结构疫苗
JP7566315B2 (ja) コンフォメーションが安定化されたrsv融合前fタンパク質
JP2025172875A (ja) パラミクソウイルスおよび/またはニューモウイルスのfタンパク質を提示する自己組織化タンパク質ナノ構造体ならびにその使用
RU2844177C2 (ru) Самосборные белковые наноструктуры, экспонирующие f-белки парамиксовируса и/или пневмовируса, и их применение
HK40128177A (en) Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
HK40014567B (en) Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
HK40014567A (en) Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220502

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220803

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220920

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221019

R150 Certificate of patent or registration of utility model

Ref document number: 7168938

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250